Find Out How Transgene’s Virus Powered Immunotherapies
Can Transform the Treatment of Solid TumorsR&D Day – Paris
September 27, 2022
–> article annonceR&D
Transgene (Euronext : TNG)
Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
Financial calendar
- May 10, 2022 - First Quarter 2022 Financial Results
- May 25, 2022 - Annual Shareholders’ Meeting
- September 7, 2022 - First Half 2022 Financial Results
- November 7, 2022 - Third Quarter 2022 Financial Results
Latest press releases
- March 16, 2023 - Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum
- March 15, 2023 - Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
- March 9, 2023 - Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
Investor Relations Contact
Lucie Larguier, +33 (0)3 88 27 91 00
Key documents
Contact Relations Investisseurs
Lucie Larguier, +33 (0)3 88 27 91 00
Financial information
Key figures
| In € million except share and per share data | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
| Revenue | 17.4 | 9.9 | 13.7 | 42.9 | 8.1 | 10.3 |
| R&D Expense | -32.9 | -27.3 | -31.4 | -27.3 | -30.4 | -26.4 |
| G&A Expense | -7.4 | -6.5 | -7.1 | -7.0 | -5.7 | -6.2 |
| Net income (loss) | -19.5 | -17.2 | -18.8 | 8.0 | -32.3 | -25.2 |
| Net Cash Burn | -10.0 | -17.0 | -20.5 | -24.5 | -28.1 | -30.6 |
| Cash & Cash Equivalents | 49.6 | 26.3 | 43.3 | 16.9 | 41.4 | 56.2 |
| Earnings/Loss per Share (Basic) | -0.21 | -0.21 | -0.23 | 0.13 | -0.52 | -0.45 |
| Earnings/Loss per Share (Diluted) | -0.20 | -0.21 | -0.23 | 0.13 | -0.52 | -0.45 |
| Shares Outstanding | 97,771,334 | 83,841,334 | 83,265,464 | 62,275,923 | 62,075,190 | 56,431,991 |
Financial reports
| Years | Quarter | Interim | Registration Document | |||
|---|---|---|---|---|---|---|
| First | Second | Third | Fourth | |||
| 2022 | ||||||
| 2021 | XBRL(fr) | |||||
| 2020 | ||||||
| 2019 | ||||||
| 2018 | ||||||
| 2017 | ||||||
| 2016 | ||||||
| 2015 | ||||||
| 2014 | ||||||
Regulated information
Monthly information on shares outstanding and voting rights (in French)
Share buyback program (in French)
Liquidity contract related information
Half-year report on the Transgene liquidity contract
- 2022: at December 31, 2022; at June 30, 2022
- 2021: at December 31, 2021; at June 30, 2021
- 2020: at December 31, 2020; at June 30, 2020
- 2019: at December 31, 2019; at June 30, 2019
- 2018: at December 31, 2018; at June 30, 2018
- 2017: at December 31, 2017; at June 30, 2017
- 2016: at December 31, 2016; at June 30, 2016
Chairman’s report on corporate governance and internal controls
Annual General Meeting information
- May 25, 2022: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 26, 2021: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 27, 2020: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 22, 2019: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 23, 2018: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 8, 2017: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 24, 2016: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 11, 2015: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 18, 2014: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
Rights issue
Stock information
General
General
| Stock Market | Euronext Paris – Eurolist (compartiment B) |
| Reuters / Bloomberg | TRNG.PA / TNG.FP |
| ISIN Code | FR0005175080 |
| Total number of shares outstanding | 100,204,071 |
| Initial Public Offering (IPO) | March 26, 1998 |
| Local Sector Index | Next Biotech / CAC Mid 100 |
| Financial Year Ends | December 31 |
Analysts
| Company | Analyst | Phone | |
|---|---|---|---|
| Bryan Garnier & Co. Ltd | Olga Smolentseva | osmolentseva@bryangarnier.com | +33 (0)1 56 68 75 57 |
| Intron Health | Naresh Chouhan | naresh@intronhealthresearch.com | +44 207 375 9143 |
| Invest Securities | Jamila El Bougrini | jelbougrini@invest-securities.com | +33 (0)1 44 88 88 09 |
| Kempen & Co. | Suzanne van Voorthuizen | suzanne.vanvoorthuizen@kempen.com | +31 (0)20 348 8484 |
| Kepler Cheuvreux | Arsene Guekam | aguekam@keplercheuvreux.com | +33 1 70 81 57 56 |
| Life Science Capital LLC | Jacques A. Villefranc | jacques@lifesciadvisors.com | +1 646 597-6997 |
| Oddo BHF | Martial Descoutures | martial.descoutures@oddo-bhf.com | +33 (0)1 44 51 85 00 |
Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.
Investor Events & Presentations
Webcasts
- March 16, 2023 - Annual results for 2022
- September 27, 2022 - Transgene R&D Day (Paris, France)
- September 7, 2022 - 2022 Half-year results and business update
- December 15, 2021 - License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO™ Platform
- November 23, 2021 - TG4050, First positive clinical data from Phase I clinical trials
- September 22, 2021 - Half-Year results 2021 & Business Update
- March 16, 2021 - 2021 Full-year results and business update
- March 11, 2021 - Full Year Results 2020, Business Update & Update on the clinical development plan of TG4001 (in French)
- March 10, 2021 - Full Year Results 2020, Business Update & Update on the clinical development plan of TG4001
- November 12, 2020 - Detailed results of the Phase 1b/2 trial of TG4001 and avelumab in advanced HPV-positive cancers presented at SITC 2020
Financial calendar
- May 10, 2022 - First Quarter 2022 Financial Results
- May 25, 2022 - Annual Shareholders’ Meeting
- September 7, 2022 - First Half 2022 Financial Results
- November 7, 2022 - Third Quarter 2022 Financial Results
Investor events
- January 9, 2023 - 26th ODDO BHF Forum – Virtual – January 9 and 10, 2023
- January 9, 2023 - LifeSci Advisors Corporate Access Event – San Francisco, USA – January 9 to 12, 2022
- January 24, 2023 - Invest Securities Biomed Forum – January 24, 2023
- January 27, 2023 - Degroof Petercam’s Virtual Healthcare Conference – January 27, 2023
- February 6, 2023 - BIO CEO & Investor Forum (New York) – February 6 to 9, 2023
Annual General Meeting
Annual General Meeting of May 25, 2022
2022 ORDINARY AND EXTRAORDINARY MEETING
Location TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE
Date and Time 25 May 2022 at 10 am – webcast (live and on-demand)
Documents
